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Background: Aberrant expression of heparanase (Hpa) is associated with apoor prognosis in ovarian and cervical
cancer patients. Inhibitors of Hpa can prevent the growth and metastasis of malignant tumor cells, and suramin
may be such a compound that has strong anti-proliferative effects on several kinds of cancer cells. We have
therefore tested whether the growth inhibiting effect of suramin on ovarian and cervical cancer cells is due to
downregulation of Hpa expression.
Results: Suramin at 300–600 μg/ml significantly inhibited HO-8910 PM and HeLa cell growth at 24 h, in both a
time-dependent and dose-dependent manner, with an IC50 of 320 μg/ml and 475 μg/ml, respectively. Suramin at
300 μg/ml significantly decreased the expression of Hpa mRNA (P < 0.005) and protein (P < 0.005) in both
HO-8910 PM and HeLa cells at 48 h.
Conclusions: The inhibitory effect of suramin on Hpa enzyme may be due to downregulating of its expression in
cancer cells. These findings confirm the importance of Hpa in tumor growth and the potential clinical application
of Hpa inhibitors in the treatment of ovarian and cervical cancer.
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Ovarian cancer is the fifth most common cause of can-
cer death among females and ranks as the first cause of
death in gynecologic malignancies. Due to no effective
early detection methods, ~70% ovarian cancers are often
diagnosed at advanced stage. With the introduction of
new treatment modalities, clinical results have been
significantly improved, but the ovarian cancer 5-year
survival rate is only 44% [1]. Uterine cervical cancer is
another major healthcare concern worldwide, especially
in the less developed countries. Despite advances in
screening, vaccination and treatment of early stage dis-
ease, advanced stage tumour, its recurrence and distant
metastasis are the main causes of treatment failure and
death. Although systemic chemotherapy or radiochemo-
therapy remains the standard treatment for those patients,
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mens are in place. Therefore, new strategies are needed to
improve survival and enhance responsiveness to cytotoxic
drugs. Molecular target treatment is more effective in
most cancers, and is now widely used. Several clinical tri-
als of molecular target treatment have demonstrated their
effectiveness in ovarian and cervical cancer [2-7]. But
some pitfalls should not be ignored, especially relating to
the problem of resistance that is a major challenge facing
clinicians. There is the need to develop a second-line
treatment strategy for the increasing number of patients
who become resistance to the molecular agents.
Hpa is an endo-β-glucuronidase that cleaves heparan
sulfate proteoglycans within the extracellular matrix,
basement membrane or on the cellular surface, directly
or indirectly enhancing cell invasion, migration, and
intravasation and extravasation, by releasing various
growth factors from heparin-binding [8-10]. Overexpres-
sion of Hpa in tumor cells markedly enhances their
growth, angiogenesis, and metastasis [11]. Ovarian and
cervical carcinomas express higher levels of Hpa mRNAdistributed under the terms of the Creative Commons Attribution License
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grade and advanced stage [12-14]. Davidson et al. [15]
reported that the expression of Hpa in ovarian cancer is
53% and 90% at the cell membrane and cytoplasm, re-
spectively. Membrane expression in >5% of tumor cells
correlates with a shorter overall survival. Immunohisto-
chemical positivity for heparanase was 63.3% (38/60) in
cervical cancer patients [14]. Hpa expression is also an
independent predictor of poor overall survival, suggest-
ing it is involved in tumor metastasis of female genital
tract malignancies [16]. Interestingly, elevated serum
Hpa levels correlate with malignant invasion and progres-
sion in ovarian cancer [17], which may facilitate disease
diagnosis and treatment surveillances. Hpa inhibitor has
strong anti-proliferation activity in vitro against two hu-
man ovarian cell lines, OVSAHO and SKOV-3 [18], and
may be one of the potential tumor molecular target thera-
peutics. A potent Hpa inhibitor, PI-88 (a Phase I/II trials
product), is effective in several types of tumor [19,20].
Hpa could lead to a new therapeutic strategy for patients
with advanced female genital tract malignancies.
Suramin (8,8′-carbonyl-bis [imino-3,1-phenylenecarbo-
nylimino (4-methyl-3,1- phenylene) carbonylimino] bis-
1,3,5-naphthalene-trisulfonic acid) was originally used to
treat African parasitic infections, such as Rhodesian and
Gambian trypanosomiasis. Due to its anti-proliferative ac-
tivity against several human tumor cell lines in dose- and
time-dependent fashion [21], suramin alone or combined
with cytotoxic drugs has been studies in many clinical
trials that include ovarian cancer [22,23]. The anti-
proliferative mechanism of suramin is still not fully
understood, but its activity may be due to it inhibiting
the binding of growth factors to their receptors and dis-
sociating receptor-bound growth factors, consequently
resulting in loss of signal transduction [24]. Suramin is
also considered a potent inhibitor of several nuclear
enzymes in vitro, including DNA primase, DNA poly-
merase α, RNA polymerase, DNA topoisomerase II, and
reverse transcriptase, which may be important to its
cytotoxic activity. Suramin and suramin analogues has
also been shown to inhibit Hpa in many human cancer
cell line by independent groups [25-28]. Suramin in-
hibits local tumor invasion and distant metastasis by
both a direct and an indirect effect on cell adhesion and
migration. New suramin analogues have now been de-
veloped to try to improve this antitumor activity and
overcome its side-effects [29].
Although suramin significantly inhibits the growth of
ovarian cancer and is used in clinical trials, its anti-
proliferative effect is not properly understood. Indeed,
this lack of knowledge of the drug’s primary mechanism
of action has prevented use of suramin in female genital
tract malignancies. Accordingly, our study has focused
on the in vitro cytotoxic activity of suramin againsthuman ovarian and cervical cancer cells. We found that
suramin significantly downregulates Hpa expression in
its inhibitory effect on the growth of cancer cells.
Results
Changes of cell morphology in HO-8910 PM cells and
HeLa cells after suramin treatment
Changes of cell morphology in HO-8910 PM cells and
HeLa cells were explored as part of its dose–response
and time–response effects. Clear changes were observed
48 and 96 h post-treatment. Cell density and non-
adhesiveness of cells began to decrease and dispersion
into single cells increased after 50 μg/ml suramin treat-
ment within 48 h. Membrane blebbing and increased
cytoplasmic volume occurred, and viable cells markedly
decreased, with dead cells floating and clumping up, in
300 μg/ml suramin within 96 h, suggesting that HO-
8910 PM cells and HeLa cells were undergoing apoptosis
(Figure 1b).
Growth changes in HO-8910P and Hela cells after suramin
treatment
The growth of the HO-8910 PM and Hela cells using
the MTTassay showed that different doses of suramin sig-
nificantly inhibited growth rate from 24 to 96 (Figure 2a).
Inhibition with 600 μg/ml suramin at 96 h reached 70.9%
in HO-8910 PM cells and 59.5% in Hela cells. Except for
the 50 μ g/ml group vs 100 μ g/ml group, inhibition of the
other groups of HO-8910 PM cells showed significant dif-
ferences (Ftime = 38.128, Ptime = 0.0001,Fdose = 44.984,
Pdose = 0.0001). For HeLa cells, except for 50 μg/ml
group vs 100 μg/ml, and vs 200 μg/ml group, inhibition
of the other groups was significantly different (Ftime =
20.548, Ptime = 0.0001,Fdose = 32.324, Pdose = 0.0001).
The IC50 values of HO-8910 PM and HeLa were
319 μg/ml, 476 μg/ml, respectively (Figure 2b).Plasma
concentration of ≥350 μg/ml suramin led to a dose-
limiting neurotoxicity [30] . At 96 h, treatment with
200 and 300 μg/ml suramin inhibited 35.1- 43.7% of
HO-8910 PM cell growth and 22.4-31.7% of Hela cell
growth, confirming the toxic nature of suramin. Flow
cytometry was used to detect apoptosis rate in HeLa
cells (Figure 2c).The level in cells given 300 μg/ml
suramin for 48 h was significantly lower than in un-
treated cells (300 μg/ml group12.91 ± 1.17%vs UCG
5.01 ± 1.07%,p =0.001).
Suramin inhibits HO-8910 PM and Hela cell proliferation
Proliferation of HO-8910 PM and HeLa cells treated
with suramin showed time-dependency and dose–de-
pendency. With increasing of dose and time, prolifera-
tion gradually decreased until 96 h. OD values of
different groups (24, 48, 72 and 96 h) and 7 different
doses(50,100,200,300,400,500,600 μg/ml)were significantly
Figure 1 Suramin decreases viability in HO-8910 PM ovarian cancer cells and Hela cervical cancer cells. HO-8910 PM and Hela cells were treated
with Hpa inhibitor Suramin (50, 100, 200, 300, 400, 500 and 600 μg/ml). The cells (1 × 104) were incubated at these concentrations for 24, 48,
72 and 96 h at 37°C in a humid air atmosphere containing 5% CO2 in RPMI-1640 culture medium. Subsequently, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added and the cells were incubated for 4 h; viability was assessed by measuring the OD at
490 nm, the value of the untreated control group (UCG) being taken as 100%. The assay showed that the HO-8910 PM and Hela cell vialibility
decreased in a dose-dependent and time-dependent manner (a,c). After 48 h treatment with 300 μg/ml suramin, morphological changes became
increasingly significant, and viable cells decreased markedly with dead cells floating and clumping in the culture media at 72 h (examined at 4-40X
magnification using a Leica DMLB microscope) (b). Statistical analysis, the one-way ANOVA.* P < 0.05 24, 48, 72 and 96 h vs the UCG; 24 vs 72 h, or
96 h; 48 vs 72 h, or 96 h; 72 vs 96 h; ●P < 0.05 100, 200, 300, 400, 500,or 600 μg/ml vs the UCG; 100 vs 300, 400, 500,or 600 μg/ml, 200,vs 300, 400, 500
or 600 μg/ml, 300 vs 400, 500, or 600 μg/ml, 400 vs 500, 600 μg/ml, 500 vs 600 μg/ml.
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Ptime = 0.0001, Fdose = 1655, Pdose = 0.0001 for HO-8910 PM;
Ftime = 126, P = 0.0001; Fdose = 768, Pdose = 0.0001 for HeLa).
For statistical analysis of inter-group OD values in both
HO-8910 PM and HeLa cells, all p values were equal to
0.0001 (0.000 is not a value) either in 4 different time
groups or in 7 different dose groups, except for the 24 h
vs 48 h groups ( Figures 3, 4, 5 and 6).
Suramin downregulates the expression of Hpa protein
and mRNA in HO-8910 PM and Hela cells
Suramin downregulation of the expression of Hpa protein
in HO-8910 PM and Hela cells was investigated by im-
munocytochemistry. From the MTT results, we selected300 μg/ml suramin and 48 h treatment as appropriate
(Figure 7b). Compact brown or yellow immune parti-
cles of Hpa protein and blue hybridized granules of
Hpa mRNA were present in the cytoplasm in the ex-
perimental control group, distributed diffusely in all
fields (Figure 7c). Staining in the suramin group de-
creased significantly in intensity as well as integration
(χ2 = 25.958, P = 0.0001,χ2 = 27.091, P = 0.0001). Real-
time quantitative-PCR was used to determine Hpa
mRNA expression in HeLa cells (Figure 3a). The level
in cells given 300 μg/ml suramin for 48 h was signifi-
cantly lower than in untreated cells (300 μg/ml group
0.92 ± 0.87vs UCG 3.62 ± 2.80, p <0.05), with down-
regulation being 3.93 fold lower.
Figure 2 Suramin decreases the proliferation of HO-8910 PM and Hela cells. MTT assay showed that HO-8910 PM and Hela proliferation was
inhibited in a dose-dependent and time-dependent manner after suramin treatment (a). IC50 value of HO-8910 PM was 319 μg/mL, IC50 value of
Hela was 319.1 μg/mL (b). Flow cytometry was used to detect apoptosis rate in HeLa cells (Figure 2c).The level in cells given 300 μg/ml suramin
for 48 h was significantly lower than in untreated cells (300 μg/ml group12.91 ± 1.17%vs UCG 5.01 ± 1.07%,p =0.001) (c).
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Suramin treatment significantly decreases cell growth in a
dose- and time-dependent manner in HO-8910 PM and
HeLa cells, consistent with previous reports [21,31,32]. Al-
though the IC50 of suramin against in HO-8910 PM cell
was 10 times higher compared with other studies, it was
lower than the cytotoxic concentrations >275 μM in hu-
man blood serum [22]. Thus suramin not only downregu-
lates Hpa protein and mRNA expression, but inhibits the
growth of cancer cells.
Suramin is a multiple sulfonic acid naphthoquinone
salt that has anti-proliferative activity against many can-
cers, with a wide range of IC50 values. Suramin at 275 μM
sustained over several weeks has been associated with
severe multitoxicity, including renal toxicity, adrenal in-
sufficiency, immune- and anticoagulant-mediated blood
dyscrasias, and dermatological toxicity [33-35]. We
found the IC50 of suramin to be 319 μg/ml, and at 200
and 100 μg/ml it could inhibit cell growth by 35.1 to
43.7%, while at 210 μg/ml it effectively decreased
CA125 serum levels of the patients with ovarian cancer.Non-cytotoxic doses of suramin ranging between 10
and 50 μM enhances the antitumor effects of several
chemotherapeutic agents in a number of tumor cell
lines [36] and several animal models [37]. Despite the
U.S. Food and Drug Administration disapproving the
use of suramin at therapeutic concentrations, 2 clinical
trials at non-cytotoxic suramin levels in combination
with chemotherapeutic agents have been conducted to
treat metastatic breast cancer [38] and advanced non-
small cell lung cancer [22], with discernible antitumor
activity being noted in the latter. Thus, low or non-
cytotoxic doses of suramin might be used as effective
chemosensitizers to cytotoxic drugs, ie as an adjuvant,
for ovarian cancer in the future.
Inhibiting the activity of key enzymes is an important
anti-proliferative mechanism of suramin at therapeutic.
A growing body of evidence has shown that suramin is
the inhibitor of such enzymes as histone methyltransfer-
ases [39], histone deacetylases [40], ATPase [41], DNA
topoisomerase [42] and Hpa [28]. However, Hpa has
been the target molecule here because it is important in
Figure 3 Viability decrease in HO-8910 PM treated with 0, 50, 100 and 200 ug/ml Suramin. Suramin decreased viability and proliferation of
HO-8910 PM cells at 50, 100, 200, 300, 400, 500 and 600 μg/ml (a,b,c,d). HO-8910 PM (1 × 104) were incubated in the presence of these
concentrations for 24, 48, 72 and 96 h at 37°C in a humid atmosphere containing 5% CO2 and 95% air in RPMI-1640 culture medium. MTT
was added and the cells were incubated for 4 h; viability was estimated by measuring the Optical density (OD) at 490 nm. The results represent the
mean ± the standard deviation (SD) of all independent experiments performed in triplicate. Statistical analysis by one-way ANOVA. * P < 0.05 50 μg/ml
48 h vs 50 μg/ml 72 h; 50 μg/ml 72 h vs 50 μg/ml 96 h (b). ●P < 0.05: 100 μg/ml 48 h vs 100 μg/ml 72 h; 100 μg/ml 72 h vs 100 μg/ml 96 h (c).
♦ P < 0.05: 200 μg/ml 48 h vs 200 μg/ml 72 h; 200 μg/ml 72 h vs 200 μg/ml 96 h (d).
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ran sulfate proteoglycans in the extracellular matrix. The
human Hpa gene is located on chromosome 4q21.3 with
a full-length cDNA of 1758 bp and its active protein
product is 50kD. Because of the inherent role of Hpa,
inhibition of its activity makes it a potential target in
anti-cancer therapy. Numerous Hpa inhibitors are being
developed and tested for growth inhibition of tumors.
PI88, one of the inhibitors, has been already used in clin-
ical trials.
New suramin analogues have been synthesized pos-
sessing highly anti-proliferative effects on tumor cells
in vitro and angiostatic effects compared with suraminitself. Marchetti et al. [28] reported that the IC50 of
suramin on Hpa activity in melanoma 70 W cells was
42 μM, much higher than the IC50 values of suramin
analogues (NF 127, NF 145 and NF 171) in a range of
20–30 μM. They also found that Hpa expressed in
70 W cells was effectively inhibited by suramin ana-
logues in a dose-dependent manner. Complete inhib-
ition was obtained at 100 μM and higher. In our study,
HO-8910 PM with its high expression of Hpa protein
and mRNA comes from a peritoneal metastasis of epi-
thelial ovarian cancer. Treatment with 300 μg/ml sura-
min significantly decreased Hpa mRNA and protein
expression at 48 h, which not only support previous
Figure 4 Viability decrease of HO-8910 PM cells treated with 300, 400, 500 and 600ug/ml Suramin (a,b,c,d). The results represent the mean ± the
standard deviation (SD) of all independent experiments performed in triplicate. Statistical analysis, the one-way ANOVA. * P < 0.05 300 μg/ml 48 h
vs 300 μg/ml 72 h; 300 μg/ml 72 h vs 300 μg/ml 96 h (a). ●P < 0.05 400 μg/ml 48 h vs 400 μg/ml 72 h; 400 μg/ml 72 h vs 400 μg/ml 96 h (b). ♦
P < 0.05 500 μg/ml 48 h vs 500 μg/ml 72 h; 500 μg/ml 72 h vs 500 μg/ml 96 h (c). ◎P < 0.05 600 μg/ml 48 h vs 600 μg/ml 72 h; 600 μg/ml 72 h
vs 600 μg/ml 96 h (d).
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lierative mechanism of suramin on ovarian cancer.
Zeng et al. [14] found 63.3% cervical cancers expressed
Hpa, and overexpression of heparanase inhibited apop-
tosis of cervical cancer cells. Ectopic heparanase overex-
pression can promote proliferation of cervical cancers
in vitro and tumor growth in vivo. High risk human pap-
illomavirus (HR-HPV) infection has been considered a
primary cause of cervical cancer because it is present in
the 99.7% of cervical cancers [43,44] , which leads to
#0.5 million cases per year. HPV 16 and 18 are the most
common HR-HPV types worldwide and account for
~70% of cervical squamous cell carcinomas and up to
85% of the adenocarcinomas. HPV16 E6 and HPV 18 E7
are best known for their ability to target the 2 tumor
suppressors, p53 and pRb [45]. The HPV16 oncogene E6
is capable of inducing overexpression of heparanase inhead and neck squamous cell carcinoma in vitro, which
can be suppressed by radiation in a dose-dependent
manner. The heparanase gene is regulated through wild-
type p53 binding to the heparanase promoter [46]. E6-
mediated degradation served as the major mechanism
inactivating p53 [47] that might lead to induction of
heparanase expression and promote cervical carcinogen-
esis. Therefore, this study provides important experi-
mental evidence of Hpa-targeted therapy for cervical
cancer. Our investigations will now focus on HPV E6 in-
hibition by suramin.
In conclusion, suramin inhibits strongly the growth of
human ovarian and cervical cancer cells, and at same time
significantly downregulates Hpa expression. We suggest
that the antitumor activity of suramin may partly relate to
inhibition of Hpa expression in cancer cells. Therefore,
combination of low dose suramin and chemotherapeutic
Figure 5 Viability decrease in Hela cells treated with 0, 50, 100 and 200ug/ml Suramin (a,b,c,d). The results represent the mean ± the Standard
deviation (SD) of all independent experiments performed in triplicate. Statistical analysis, the one-way ANOVA. * P < 0.0 50 μg/ml 48 h vs 50 μg/ml
72 h; 50 μg/ml 72hs vs 50 μg/ml 96 h (b). ●P < 0.05 100 μg/ml 48hs vs 100 μg/ml ;100 μg/ml 72 h vs 100 μg/ml 96 h (c). ♦ P < 0.05 200 μg/ml 48 h
vs 200 μg/ml 72 h; 200 μg/ml 72 h vs 200 μg/ml 96 h (d).
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might be a suitable means of treatment in the future.
Conclusions
Suramin as a Hpa inhibitor can inhibit the growth of
HO-8910 PM and HeLa cells and at same time signifi-
cantly downregulates Hpa expression.
Methods
Cell lines and reagents
Human ovarian cancer cell line, HO-8910 PM, classified
as a highly malignant peritoneal metastatic carcinoma
with a highly metastatic potential, was obtained from
Shanghai institutes for biological sciences (Shanghai,
China). Human Cervical cancer line Hela was alsoobtained from the same source. Suramin as its sodium
salt was purchased from EMD Millipore (Billerica, MA,
USA). Hpa antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). SP immunohisto-
chemical and DAB kits were purchased from the Beijing
Sequoia (Beijing, China). The biotin-labeled Hpa probe
was obtained from Beijing Aoke biotechnology company
(Beijing, China), and the mRNA sequence was 5′TCA
ATG GTG ACG GAC AGG AAC GAG G 3′. In situ
hybridization reagent box was the production of Boster
(Wuhan, China).
Culture
HO-8910 PM and Hela cells were cultured in RPMI-
1640 (Logan, UT, USA) supplemented with 10% fetal
Figure 6 Viability decrease in the Hela cells treated with 300, 400, 500 and 600ug/ml Suramin (a,b,c,d). The results represent the mean ± the
Standard deviation (SD) of all independent experiments performed in triplicate. Statistical analysis, the one-way ANOVA. * P < 0.05 300 μg/ml 72 h
vs 300 μg/ml 96 h (a). ●P < 0.05 400 μg/ml 48 h vs 400 μg/ml 72 h;400 μg/ml 72 h vs 400 μg/ml 96 h (b). ♦ P < 0.05 500 μg/ml 24 h vs 500 μg/ml
48 h (c). ◎P < 0.05 600 μg/ml 48 h vs 600 μg/ml 72 h; 600 μg/ml 72 h vs 600 μg/ml 96 h (d).
Li et al. Cancer Cell International  (2015) 15:52 Page 8 of 11bovine serum and incubated at 37°C in a humidified
incubator with air plus 5% CO2. The cells at 80% con-
fluence in logarithmic growth phase were used for ex-
periments. Viability was >95%, as estimated by trypan
blue staining.
Preparation of adherent cell slides
HO-8910 PM and Hela cells in logarithmic growth
phase were detached by digesting with 0.25% trypsin
plus 0.02% EDTA. One × 104 cells in 1 ml RPMI-1640
medium supplemented with 10% FBS were seeded on to
coverslips pre-placed in welsl in a 24-well plate. After at-
tachment of 70-80%, the medium was poured off and
the layer washed twice with ice-cold PBS. The coverlips
were removed and transferred to new fresh 24-well
plates. They were incubated in 4% paraformaldehyde at
4°C for 30 min and washed twice with PBS before being
kept at 20°C for a week.MTT assay
Cells were seeded in culture medium in a 96-well plate
at 1 × 104 cells/well. After overnight incubation, cells
were treated with different concentrations of suramin.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assay was used to measure tumor cell
viability at from after 24 to 96 h of incubation. The
cells were then stained with MTT (Amresco, Solon,
OH, USA) for 4 h. The medium was discarded, and the
cells were solubilized with 150 μl DMSO for 15 min,
and the plate shaken gently for 10–15 min. The wells
without suramin treatment were used as the untreated
control groups, and sextuplicate wells were tested for
each concentration. Each experiment was repeated 3
times. Photometric value A (OD value) at 490 nm was
measured by a microplate reader. Growth inhibition
rate (GI) was calculated according to the following
formula:
Figure 7 Effect of suramin on Hpa protein and mRNA expression HO-8910 PM and the Hela cells. Slides of 48 h post-treatment with 300 μg/ml
were selected for study. Both groups were tested in sextuplicate, and the experiment was repeated 3 times. Expression of Hpa protein was followed by SP
immunohistochemical staining. Sections of colon cancer tissues positive for Hpa protein expression were used as the positive control, while antibody
diluent replaced the antibody in the negative control. Compact brown or yellow immune particles of Hpa protein were present in the cytoplasm in
the UCG, which distributed diffusely in all fields. The staining signals of Hpa protein in 300 μg/ml group decreased significantly in intensity as well as
integration seen with a zoom lens of 40X by microscopy (b). HO-8910 PM cell Hpa mRNA expression was measured by an in situ hybridization kit. The
slides were processed with an excessive amount RNA enzyme as the negative control. Sections of colon cancer tissues were used as the positive
control. Compact blue hybridized granules of Hpa mRNA were present in the cytoplasm of the UCG, which distributed diffusely in all fields. The
staining signals of Hpa mRNA in the 300 μg/ml group decreased significantly in intensity as well as integration (c). Real-time quantitative-PCR was used
to determine Hpa mRNA expression in HeLa cells (a); its level in cells treated with 300 μg/ml suramin for 48 h was significantly lower than in untreated
cells (300 μg/ml group 0.92 ± 0.87vs UCG 3.62± 2.80). Statistical analysis, chi-square test; *P <0.05. Hpa protein expression of 48 h post-treatment in the
300 μg/ml group vs the UCG; ●P < 0.05. Hpa mRNA expression of 48 h post-treatment in the 300 μg/ml group vs UCG.
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Immunocytochemistry
Hpa expression was examined by the SP immunohisto-
chemical method. Briefly, after treated with 3% hydrogen
peroxide for 20 min, cell slides were incubated overnight
at 4°C with primary anti-Hpa antibody (1: 100). DAB
(Diaminobenzidine) staining was given for 10 min. Follow-
ing hematoxylin counterstaining, the slides were sealed
with neutral gum. Sections of colon cancer tissues positive
for Hpa expression were used as control, while antibody
diluent replaced the Hpa antibody as the negative control.The slides of suramin treatment were defined as the
experiment group, and slides without suramin were the
untreated controls. Both groups were tested in sextupli-
cate, and the experiment was repeated 3 times.
In situ hybridization
The equipment and buffers were treated for the
hybridization test with diethylpyrocarbonate (DEPC,
Sigma-Aldrich, St Louis, MO, USA). After being washed
with 50 and 30% alcohol, sterile water and PBS at room
temperature, the cells on the slides were permeated in
0.3% Triton X-100/PBS for 10 min and digested with 3%
pepsin diluted in fresh citric acid for 20 min at 37°C.
After being washed in PBS for 5 min, the slides were
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room temperature. Each slide was dripped with 20 μl
hybridization solution and pre-hybridized in the wet
box at 37°C for 3-4 h. Hpa probe (6–12 ng/20 μl) was
added to each slide. The slides were covered with wax
membrane and hybridized for 12 ~ 16 h at 42 ~ 43°C,
The slides were washed followed by washing four times
in 0.2× SSC at 42°C for 15 min. They were then incu-
bated in 1% acetylated BSA at 20°C for 10 min and in
freshly diluted buffer SA-AP (Promega, Madison, WI)
for 20 min at 37°C. After washing with Tris–HCl buffer
I 3 times and in Tris–HCl buffer II twice, the slides
were protected from light and colored in freshly pre-
pared BCIP/NBT (Promega) for 100–120 min. They
were then stained with nuclear fast red for several min
and sealed with neutral gum. The negative experimen-
tal control slides were processed with an excess of
RNA enzyme. Sections of colon cancer tissues with
positive expression of Hpa were used as positive ex-
perimental controls. Both groups were tested in sextu-
plicate, and the experiment was repeated 3 times.
Interpretation of immunocytochemistry and in situ
hybridization results
Positive expression of Hpa protein was determined
by yellow, brown and tan particles in the cytoplasm
(Figures 2A and B). Hpa mRNA was colored by
NBT/BCIP, as shown in blue and purple granules. Positive
signals were located in the cytoplasm (Figures 2C and D).
Five high-perspectives under binocular microscope were
selected in each slide, and 100 cells were counted ran-
domly per field. Expression of Hpa protein and mRNA
were scored based on integrated staining intensity and by
the proportion of positive cells [48]. The percentage of
positively stained cells was scored as 1 (<5%, negative), 2
(5-25%, sporadic), 3 (25-50%, focal) or 4 (>50%, diffuse).
Intensity of the hybridization signal was divided into 4
grades: no staining (1 score), weak (2 score), moderate
(3 score) and strong (4 score). According to the prod-
uct of the scores of positive cells and the scores of
staining intensity, the expression level was defined as
follows: 1+ (<4 scores), ++ (4–8 scores), +++ (9–12
scores), ++++ (13–16 scores).
TaqMan real-time qRT–PCR
For TaqMan real-time qRT–PCRs, Hpa and b2-
microglobulin were purchased from Ambion (Carlsbad,
CA, USA; ID: Hs00935033_m1, and 4333766 F, respect-
ively). PCRs were done with the ABI 7500 Fast Real
Time PCR System (Applied Biosystems, Foster City,
CA, USA). Amplification conditions were 2 min at 50°C,
10 min at 95°C and then 40 cycles each consisting of 15 s
at 95°C and 1 min at 60°C. Hpa relative expression was
assessed using the comparative CT method and presentedas 2-Δct value. The fold changes of Hpa expression were
calculated according to reference [49].
Statistical methods
SPSS10.0 software package (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis and calculating the
IC50 of suramin. The values represent the mean ± the SD
of the values obtained. In some experiments, the GI%
was calculated, which represents the percentage increase
or decrease in relation to the untreated control group.
One way ANOVA was used to make comparisons be-
tween the groups. For the count data, the Chi-square test
was used to calculate the significance of differences be-
tween the groups, with p < 0.05 being taken as significant.
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